In Brief: Perkin-Elmer/PerSeptive Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Perkin-Elmer/PerSeptive Biosystems: Hart-Scott-Rodino antitrust review of Perkin-Elmer's proposed $360 mil. acquisition of PerSeptive is extended as a result of a Department of Justice request for additional information related to the transaction. A definitive agreement for the deal was announced Aug. 25 ("The Gray Sheet" Sept. 1, p. 6). Both firms offer mass spectrometry products that enable lab technicians to analyze and sequence peptide and protein biomolecules; the firms maintain that their respective technologies are used in different phases of the drug discovery process. In addition to regulatory approval, the deal is contingent on a vote by PerSeptive shareholders, a meeting of which is slated for Dec. 4...
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.